성윤경
2019-04-29T06:13:18Z
2019-04-29T06:13:18Z
2016-12
대한내과학회지, v. 91, NO 3, Page. 250-256
1738-9364
2289-0769
http://ekjm.org/journal/view.php?doi=10.3904/kjm.2016.91.3.250
https://repository.hanyang.ac.kr/handle/20.500.11754/102924
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation. There are two kinds of NSAID classified according to the selectivity of COX-2 inhibition: non-selective NSAIDs and cyclooxygenase (COX)-2 inhibitors. Non-selective NSAIDs have a high incidence of gastrointestinal and bleeding-associated adverse events, while COX-2 inhibitors are safer in terms of these events. However, COX-2 inhibitors are thought to cause increased cardiovascular events. The COX-2 inhibitors rofecoxib and valdecoxib were withdrawn from the market over safety concerns. Three COX-2 inhibitors are now available in South Korea after the recent approval of etoricoxib and polmacoxib for osteoarthritis patients. After reviewing the history of and recent studies about the safety of COX-2 inhibitors, physicians should find new uses for old drugs. (Korean J Med 2016;91:250-256)
ko_KR
대한내과학회
비스테로이드 소염제
사이클로옥시제나제 저해제
안전성
Anti-inflammatory agents
Non-steroidal
Cyclooxygenase inhibitors
Safety
새로운 COX-2 억제제
New COX-2 Inhibitors
Article
3
91
10.3904/kjm.2016.91.3.250
250-256
대한내과학회지
김담
성윤경
Kim, Dam
Sung, Yoon-Kyoung
2016018936
S
COLLEGE OF MEDICINE[S]
DEPARTMENT OF MEDICINE
sungyk